Quantcast

Latest B-cell chronic lymphocytic leukemia Stories

2014-01-07 12:27:02

RARITAN, N.J., Jan. 7, 2014 /PRNewswire/ -- Janssen Research & Development, LLC today announced the early stopping of PCYC-1112-CA, the Phase 3 study of IMBRUVICA(TM) (ibrutinib) in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), based on the recommendation of an Independent Data Monitoring Committee (IDMC), which concluded that the study showed a significant difference in progression-free survival (PFS) as compared to the control, the...

2014-01-07 12:26:56

SUNNYVALE, Calif., Jan. 7, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that an Independent Data Monitoring Committee (IDMC) unanimously recommended that the Phase III RESONATE study, PCYC-1112-CA, a head-to-head comparison of IMBRUVICA(TM) (ibrutinib) versus ofatumumab, be stopped early because the primary and a key secondary endpoint of the study have been met. At the planned interim analysis, the Phase III RESONATE study demonstrated that IMBRUVICA showed...

Engineered Immune Cells Fight Cancer
2013-12-09 14:30:13

Brett Smith for redOrbit.com - Your Universe Online Researchers from the University of Pennsylvania and the Children’s Hospital of Philadelphia have been able to reprogram the body’s immune system to fight leukemia, with 89 percent of children and adults in a series of clinical trials showing no evidence of cancer after receiving a personalized cell therapy. The findings from the first 59 patients to receive this cutting-edge therapy, known as CTL019, were presented during the...

2013-12-09 10:12:57

A series of advancements in genetically engineered cell therapies demonstrate early efficacy and safety in patients with blood disorders for whom standard treatments have been unsuccessful, according to data showcased today during the 55th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans. Today, many patients with newly diagnosed blood disorders – ranging from cancer to rare genetic conditions – respond well to modern treatment regimens. However, for...

Genetically Modified Cells Produce Long-term Remissions
2013-12-09 06:46:50

University of Pennsylvania School of Medicine Three and a half years after beginning a clinical trial which demonstrated the first successful and sustained use of genetically engineered T cells to fight leukemia, a research team from the Perelman School of Medicine at the University of Pennsylvania and the Children's Hospital of Philadelphia will today announce the latest results of studies involving both adults and children with advanced blood cancers that have failed to respond to...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related